Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Renerve Limited ( (AU:RNV) ) is now available.
ReNerve Limited has announced significant changes to its Board of Directors as part of a renewal process. The company has appointed Maja McGuire as interim Chair and Dr. Paul Savage as Non-Executive Directors, while Stephen Cooper and Dr. Michael Panaccio have resigned. These appointments aim to leverage McGuire’s extensive experience in corporate strategy and governance and Savage’s expertise in biomedical science to drive the company’s transformation into a commercial medical device entity. The changes are expected to enhance ReNerve’s industry positioning and support its ongoing R&D and commercial development programs.
More about Renerve Limited
ReNerve Limited (ASX:RNV) is an Australian biotechnology company specializing in medical devices for peripheral nerve injury (PNI) repair. Founded by a neurosurgeon and medtech researchers, the company is known for its innovative, ready-to-use solutions that have revolutionized peripheral nerve surgery, delivering improved outcomes for patients globally.
Average Trading Volume: 562,853
Technical Sentiment Signal: Strong Sell
Find detailed analytics on RNV stock on TipRanks’ Stock Analysis page.